Press release
Schizophrenia Therapeutics Pipeline Assessment | Clinical and Non-Clinical Studies, Emerging Therapies, Treatment Algorithm, and Key Companies | Delveinsight
Schizophrenia Therapeutics
"Schizophrenia Pipeline Insight, 2022" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Schizophrenia Therapeutics Market.
The report provides a detailed description of the drug, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any). The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.
Request for Sample Report:
https://www.delveinsight.com/report-store/schizophrenia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Schizophrenia Pipeline Analysis
The report provides insights into:
The report provides detailed insights about companies that are developing therapies in the Schizophrenia Market.
It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Schizophrenia treatment.
Schizophrenia key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Schizophrenia Drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Schizophrenia market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Request for Sample PDF: https://www.delveinsight.com/sample-request/schizophrenia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Schizophrenia Therapeutics Analysis
Globally, there are approx. 70+ key companies which are developing therapies for Schizophrenia. Otsuka Pharmaceutical is leading the therapeutics segment, with its therapeutic candidate in the most advanced stage of clinical development, i.e., phase III.
Some of the leading companies in the Schizophrenia Market include:
• Otsuka Pharmaceutical
• Gedeon Richter Ltd.
• Neurocrine Bioscience
• Takeda Pharmaceutical Company
• Memory Pharmaceuticals
• Hoffmann-La Roche
• H. Lundbeck
• Organon and Co
• Meiji Seika Pharma Co., Ltd.
• SK Life Science, Inc.
• Novartis Pharmaceuticals
• Vanda Pharmaceuticals
• Alkermes, Inc.
• Solvay Pharmaceuticals
• Sumitomo Dainippon Pharma Co., Ltd.
• Mitsubishi Tanabe Pharma Corporation
• SyneuRx International (Taiwan) Corp
• BioXcel Therapeutics Inc
• Cognitive Research Corporation
• Amarex Clinical Research
• Forum Pharmaceuticals Inc
• Amneal Pharmaceuticals, LLC
• Accutest Research Laboratories (I) Pvt. Ltd.
• Eli Lilly and Company
• Johnson & Johnson Pharmaceutical Research & Development, L.L.C
• Janssen, LP
• Delpor, Inc.
• Cerevel Therapeutics, LLC
• Zogenix, Inc.
• Reviva Pharmaceuticals
• Alkermes, Inc.
• Karuna Therapeutics
And Several Others.
Schizophrenia Therapies covered in the report include:
• Ulotaront (Otsuka Pharmaceutical)
• Luvadaxistat (Takeda)
• CY6463 (Cyclerion Therapeutics)
• AVP 786 (Avanir Pharmaceuticals)
And many more
DelveInsight's report covers around 70+ products under different phases of clinical development like -
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
Request the Sample PDF to Get a more in-depth Assessment: https://www.delveinsight.com/report-store/schizophrenia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Table of Content
1. Report Introduction
2. Executive Summary
3. Schizophrenia Current Treatment Patterns
4. Schizophrenia - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Schizophrenia Late Stage Products (Phase-III)
7. Schizophrenia Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Schizophrenia Discontinued Products
13. Schizophrenia Product Profiles
14. Schizophrenia Key Companies
15. Schizophrenia Key Products
16. Dormant and Discontinued Products
17. Schizophrenia Unmet Needs
18. Schizophrenia Future Perspectives
19. Schizophrenia Analyst Review
20. Appendix
21. Report Methodology
*The table of contents is not exhaustive; the final content may vary.
Request for the Sample PDF (to get a detailed understanding of the TOC, Tables, and Figures included in the report), at: https://www.delveinsight.com/sample-request/schizophrenia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Contact Info:
Anuj Rawat
Email: info@delveinsight.com
https://www.delveinsight.com/
Request for Sample Copy of the Report at:
https://www.delveinsight.com/report-store/schizophrenia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Schizophrenia Therapeutics Pipeline Assessment | Clinical and Non-Clinical Studies, Emerging Therapies, Treatment Algorithm, and Key Companies | Delveinsight here
News-ID: 2688745 • Views: …
More Releases from DelveInsight Business Research
Alpha-1 Antitrypsin Deficiency Pipeline 2025: MOA and ROA Insights, Clinical Tri …
Alpha-1 Antitrypsin Deficiency pipeline constitutes 12+ key companies continuously working towards developing 12+ Alpha-1 Antitrypsin Deficiency treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Alpha-1 Antitrypsin Deficiency Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Alpha-1 Antitrypsin Deficiency Market.
The Alpha-1 Antitrypsin Deficiency Pipeline report embraces in-depth commercial…
Alopecia Areata Market Expected to Gain Momentum Through 2034, According to Delv …
The Alopecia Areata market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Alopecia Areata pipeline products will significantly revolutionize the Alopecia Areata market dynamics.
DelveInsight's "Alopecia Areata Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Alopecia Areata, historical and forecasted epidemiology as well as the Alopecia Areata market trends in the United…
Acne Vulgaris Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Tria …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Acne Vulgaris pipeline constitutes 20+ key companies continuously working towards developing 22+ Acne Vulgaris treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Acne Vulgaris Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also…
Stargardt Disease Market Dynamics Indicate Upward Trajectory Through 2034, Repor …
The Stargardt Disease market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Stargardt Disease pipeline products will significantly revolutionize the Stargardt Disease market dynamics.
DelveInsight's "Stargardt Disease Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Stargardt Disease, historical and forecasted epidemiology as well as the Stargardt Disease market trends in the United…
More Releases for Schizophrenia
Rising Mental Illness Burden Fuels Growth In The Schizophrenia Market: Critical …
Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Schizophrenia Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
The financial scope of the schizophrenia market has shown consistent expansion lately, projected to see an increase from a valuation of $5.82 billion in 2024 to $6.06 billion by 2025, reflecting a compound annual growth rate…
Rising Mental Illness Burden Fuels Growth In The Schizophrenia Market: Pivotal F …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts
Schizophrenia Market Size Growth Forecast: What to Expect by 2025?
In the past few years, the schizophrenia market size has seen robust growth. The projected growth from $5.82 billion in 2024 to $6.11 billion in 2025, signifies a compound annual growth rate (CAGR) of 5.0%. Factors such as increased…
Schizophrenia Drugs Market Opportunity | Size | Research Report
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲: Schizophrenia Drugs Market was valued at USD 5.3 Billion in 2018 and is projected to reach USD 8.42 Billion by 2026, growing at a CAGR of 3.66% from 2019 to 2026.
Market Overview for Schizophrenia Drugs Market
Schizophrenia Drugs Market OverviewThe schizophrenia drugs market is experiencing significant growth driven by advancements in pharmacotherapy and increasing awareness about mental health disorders. Schizophrenia, a chronic and severe mental disorder affecting millions…
Schizophrenia Drugs Market - Restoring Balance, Inspiring Hope: Schizophrenia Dr …
Newark, New Castle, USA: The "Schizophrenia Drugs Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Schizophrenia Drugs Market: https://www.growthplusreports.com/report/schizophrenia-drugs-market/7871
This latest report researches the industry structure, sales, revenue,…
Schizophrenia Drugs Market - Leading the Way in Schizophrenia Treatment: Nurturi …
Newark, New Castle, USA - new report, titled Schizophrenia Drugs Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Schizophrenia Drugs market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Schizophrenia Drugs market. The report offers an overview of the market, which…
Schizophrenia Drug Market & Pipeline Insight
Schizophrenia is defined as a disorder of the brain which impacts the way in which a person acts, thinks, and sees the world. It has been observed that the patients suffering from schizophrenia generally tend to have an altered perception of reality, which reveals a significant diversion from the reality. In most cases, schizophrenia is diagnosed among people in the late teens or early adulthood. However, middle-aged people also could…
